(Q36643122)

15 August 2017

1 reference

title

Complete metastasectomy in patients with stage IV metastatic melanoma (English)

1 reference

15 August 2017

1 reference

David W Ollila

1

1 reference

15 August 2017

publication date

1 November 2006

1 reference

Lancet Oncology Commission

15 August 2017

published in

1 reference

15 August 2017

volume

7

1 reference

15 August 2017

issue

11

1 reference

15 August 2017

page(s)

919-924

1 reference

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Gr

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Long term response to chemotherapy in patients with visceral metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Effect of temozolomide on central nervous system relapse in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

The distribution of secondary growths in cancer of the breast. 1889

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Surgical resection for melanoma metastatic to the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Contemporary surgical treatment of advanced-stage melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Surgical treatment for metastatic malignancies. Anatomical resection of liver metastasis: indications and outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Pulmonary metastases from uterine malignancies: results of surgical resection in 133 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Recurrence patterns and outcome in 1019 patients undergoing axillary or inguinal lymphadenectomy for melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

The natural history of resectable metastatic melanoma (Stage IVA melanoma).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Impact of 2-deoxy-2[F-18]fluoro-D-glucose Positron Emission Tomography on the management of patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Prognostic factors for survival of patients treated systemically for disseminated melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Prognosis after initial recurrence of cutaneous melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Role of surgery in patients with stage IV melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Improved survival after resection of pulmonary metastases from malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Lung metastases from melanoma: when is surgical treatment warranted?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

METASTATIC MELANOMA OF THE GASTROINTESTINAL TRACT

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Metastatic pattern of malignant melanoma. A study of 216 autopsy cases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Gastrointestinal metastases from malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Surgery for melanoma metastatic to the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

Role of surgical intervention in the management of intestinal metastases from malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970938-X

7 January 2021

10.1016/S1470-2045(06)70938-X

Identifiers

DOI

1 reference

15 August 2017

1 reference